United States Patent and Trademark Office Grants Patent for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
United States Patent and Trademark Office Grants Patent for Vectra(R) DA

SALT LAKE CITY, Dec. 1, 2015 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN ), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent No. 9,200,324. The patent, which is expected to expire in 2031, provides intellectual property protection for Crescendo Bioscience's Vectra ® DA testing.

Vectra DA is an advanced blood test for adults with rheumatoid arthritis (RA) and helps patients objectively track their disease activity over time. Vectra DA measures expression levels of twelve biomarkers that are then combined into a single score. The twelve biomarkers measured by Vectra DA are: VCAM-1, EGF, VEGF-A, IL-6, TNF-RI, MMP-1, MMP-3, YKL-40, leptin, resistin, SAA and CRP.

The recently issued patent is co-assigned to Crescendo and the Oklahoma Medical Research Foundation and is the first patent issued relating to Vectra DA. Crescendo will continue to pursue additional patent applications, which if issued, should expand the scope of intellectual property protection for Vectra DA.

"Crescendo's first patent for Vectra DA is significant because it validates the innovation required to bring to market the only objective multi-biomarker test for assessing RA disease activity," said Bernie Tobin, president, Crescendo Bioscience. "The PTO's decision comes at a critical time as we enter the golden era of personalized medicine.  In order for personalized medicine to become a reality, strong intellectual property protection is essential because it provides research-based companies like Crescendo with incentives to continue to invest in research and development."

About Vectra ® DA

Vectra DA is the only multi-biomarker blood test for rheumatoid arthritis (RA) disease activity that integrates the concentrations of 12 serum proteins associated with RA disease activity into a single objective score, on a scale of 1 to 100, to help physicians make more informed treatment decisions. Vectra DA testing is performed at the Crescendo Bioscience state-of-the-art CLIA (Clinical Laboratory Improvement Amendments) facility. Test results are reported to the physician 5 to 7 days from shipping of the specimen to Crescendo Bioscience. Physicians can receive test results via standard mail, by fax or via the private web portal, VectraView. For more information on Vectra DA, please visit: www.Vectra-DA.com .

About Crescendo Bioscience

Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc., is a molecular diagnostics company dedicated to developing and commercializing quantitative blood tests for rheumatoid arthritis (RA) and other autoimmune diseases, located in South San Francisco, Calif.  Crescendo Bioscience develops quantitative, objective, reproducible blood tests to provide rheumatologists with deeper clinical insight to help enable more effective management of patients with autoimmune and inflammatory diseases.  For more information, please visit the company website at www.CrescendoBio.com .

About Myriad Genetics

Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com .

Myriad, the Myriad logo, BART, BRAC Analysis , Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to Patent No. 9,200,324 providing intellectual property protection for Vectra ® DA testing and the expected patent expiration date; the ability of Vectra DA to help patients objectively track their disease activity over time; the Company's continued pursuit of additional patent applications; the scope of intellectual property protection of future patents for Vectra DA; and the Company's strategic directives under the captions "About Crescendo Bioscience" and  "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers' reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2015, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Media Contact: Ron Rogers (801) 584-3065 Investor Contact: Scott Gleason (801) 584-1143

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 19

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 328

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 244

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 258

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 467

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 21

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 360

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Ericsson Completes Major Buyback in November Burst

Updated Category News Views 22

Ericsson's Aggressive Share Repurchase Strategy Ericsson's share buyback spree might not be the first rodeo for seasoned investors out there, but their recent grab between November 9th and 13th surely made a few heads turn. The telecom giant snatched up a neat pile of 500,000 of its own Class B shares, maintaining the steady tick of their ambitious buyback program. It's...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 69

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading

Top 5 Most Recently Viewed Articles

BETR Faces Securities Fraud Actions Post-Misleading Statements

Updated Category News Views 123

Unpacking the Legal Drama Around BETR The tale of Better Home & Finance Holding Company (BETR) is like a roadside crash you can't help but stare at. We're talking big, ugly losses and a chance for investors who got roughed up to throw some punches back with a securities fraud class action. The legal honchos at Howard G. Smith's law office are rallying the troops. If...

Continue Reading
Dorian LPG Faces Market Challenges But Holds Strong Financials

Updated Category News Views 133

Dorian LPG Stock Performance Overview In a challenging market environment, Dorian LPG Ltd. (NYSE: LPG) stock has recently touched a 52-week low, with shares falling to $24.86. This significant drop highlights a broader trend in the industry, as the company grapples with headwinds leading to a troubling one-year change of -38.78%. Investors are closely monitoring the stock...

Continue Reading
Copenhagen Airports A/S Annual General Meeting Announcement

Updated Category News Views 115

Upcoming Annual General Meeting of Copenhagen Airports A/S Shareholders are invited to participate in the Annual General Meeting of Copenhagen Airports A/S. This important event will take place on the scheduled date and time, providing an opportunity for stakeholders to engage with the management and stay informed about the company's direction. Notice of Meeting Details...

Continue Reading
Important Notice for Shareholders of KinderCare Learning

Updated Category News Views 131

Key Notice for KinderCare Learning Companies, Inc. Shareholders The Gross Law Firm has issued a crucial notice directed at shareholders of KinderCare Learning Companies, Inc. (NYSE: KLC) regarding a class action lawsuit. This communication is particularly relevant to those who acquired shares during the designated class period. Shareholders are strongly encouraged to make...

Continue Reading
Discover the New Romantic Getaway at Cicada Resort Bali Ubud

Updated Category News Views 350

Welcome to Cicada Resort Bali Ubud Cicada Resort Bali Ubud, Autograph Collection, located in Sebatu's tranquil environment, extends a warm invitation to travelers seeking a romantic retreat. The resort has recently become part of the prestigious Autograph Collection, contributing to its expanding presence in the hospitality space. Embrace Nature and Culture Just a short...

Continue Reading